I’m a board-certified radiation oncologist in the Department of Radiation Oncology at Emory University School of Medicine. My practice includes the treatment of thoracic, gynecologic, and genitourinary cancers utilizing standard radiation techniques. Additionally, I utilize specialized high dose techniques such as HDR brachytherapy and stereotactic body and cranial radio surgeries (SBRT, SRS).
Joseph W. Shelton, MD
Medical Director, Radiation Oncology
- Radiation Oncology
- ABMS Radiology
Education & Training
- Medical School: University of North Carolina at Chapel Hill
- Internship: Emory University School of Medicine
- Residency: Emory University School of Medicine
Heumann TR, Diaz R, Liu Y, Hanley K, Bang S, Horowitz IR, Khanna N, Shelton JW. Clinical outcomes and the role of adjuvant therapy sequencing in Type II uterine cancer following definitive surgical treatment. European J of Gyn Oncol. Accepted, In Press
Cassidy RJ, Zhang X, Patel PR, Shelton JW, Escott CE, Sica GL, Rossi MR, Hill CE, Steuer CE, Pillai RN, Ramalingam SS, Owonikoko TK, Behera M, Force SD, Fernandez FG, Curran WJ, Higgins KA. Next Generation Sequencing andClinical Outcomes of Lung Adenocarcinomas Treated with Stereotactic Body Radiotherapy. Cancer. Accepted. In Press
Schreibmann E, Schuster DM, Rossi PJ, Shelton J, Cooper S, Jani AB. Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. Int J Radiat Oncol Biol Phys. 2016;96(1):206-213.
Ryckman JM, Shelton JW, Waller AF, Schreibmann E, Latifi K, Diaz R. Anatomic structure-based deformable image registration of brachytherapy implants in the treatment of locally advanced cervix cancer. Brachytherapy. 2016;15(5):584-592.
Jani AB, Schreibmann E, Rossi PJ, Shelton J, Godette K, Nieh P, Master VA, Kucuk O, Goodman M, Halkar R, Cooper S, Chen Z, Schuster DM. Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. J Nucl Med. 2017 Mar;58(3):412-418.
Cheng J, Squires MH 3rd, Mikell JL, Fisher SB, Staley CA 3rd, Kooby DA, El-Rayes BF, Curran WJ Jr, Hall WA, Colbert LE, Shelton JW, Maithel SK, Landry J, Yu DS. Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. J Gastrointest Oncol. 2015;6(3):247-253.
Marcus DM, Lowe M, Khan MK, Lawson DH, Crocker IR, Shelton JW, Melton A, Maynard N, Delman KA, Carlson GW, Rizzo M. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol. 2014;37(6):580-584.
Hall WA, Petrova AV, Colbert LE, Hardy CW, Fisher SB, Saka B, Shelton JW, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Volkan Adsay N, Curran WJ, Landry JC, Maithel SK, Yu DS. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Oncogene. 2014;33(47):5450-5456.
Das S, Liu T, Jani AB, Rossi P, Shelton J, Shi Z, Khan MK. Comparison of image-guided radiotherapy technologies for prostate cancer. Am J Clin Oncol. 2014;37(6):616-623.
Colbert LE, Petrova AV, Fisher SB, Pantazides BG, Madden MZ, Hardy CW, Warren MD, Pan Y, Nagaraju GP, Liu EA, Saka B, Hall WA, Shelton JW, Gandhi K, Pauly R, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Cancer Res. 2014;74(10):2677-2687.
Yang X, Rossi P, Bruner DW, Tridandapani S, Shelton J, Liu T. Noninvasive evaluation of vaginal fibrosis following radiotherapy for gynecologic malignancies: a feasibility study with ultrasound B-mode and Nakagami parameter imaging. Med Phys. 2013;40(2):022901.
Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, El-Rayes B, Shu HK. In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARPInhibitor ABT-888 in Colorectal Cancer Cells. International Journal of Radiation Oncology* Biology* Physics. 2013;86(3):469-476.
Hall WA, Colbert L, Nickleach D, Shelton J, Marcus DM, Switchenko J, Rossi PJ, Godette K, Cooper S, Jani AB. Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate. Pract Radiat Oncol. 2013;3(4):e157-164.
Colbert LE, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW, Petrova AV, Warren MD, Pantazides BG, Gandhi K, Kowalski J, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Curran WJ Jr, Landry JC, Maithel SK, Yu DS. Pronecrotic mixed lineage kinase domain‐like protein expression is a prognostic biomarker in patients with early‐stage resected pancreatic adenocarcinoma. Cancer. 2013;119(17):3148-3155.
Shelton J, Rossi PJ, Chen H, Liu Y, Master VA, Jani AB. Observations on prostate intrafraction motion and the effect of reduced treatment time using volumetric modulated arc therapy. Pract Radiat Oncol. 2011;1(4):243-250.